AccuVAC-IN002

AccuVAC-IN002 is an investigational intranasal COVID-19 vaccine developed by Defence Therapeutics as a second-generation, non-injectable SARS-CoV-2 vaccine built on the company's Accum platform. Public company materials describe it as a preclinical mucosal vaccine formulation intended to induce both systemic and mucosal antibody responses, including IgA and IgG, with the goal of reducing infection and viral shedding. The specific antigen composition, exact vaccine construct, and detailed molecular mechanism have not been clearly disclosed in the accessible public sources, so its mechanism is best characterized as an Accum-enabled intranasal SARS-CoV-2 vaccine candidate for prophylaxis against COVID-19 rather than a fully specified drug substance.

Other names

AccuVAC-IN002AccuVAC-IN-002AccuVAC-IN 002